Almac Group awarded grant from the Covid-19 Therapeutics Accelerator

Almac Sciences, a member of the Craigavon-headquartered Almac Group, has been awarded a grant of $500,000 by the Covid-19 Therapeutics Accelerator towards developing cost effective, scalable processes for the production of the active pharmaceutical ingredient (API) of the drug remdesivir.
By Claire Cartmill
Published 20th Nov 2020, 13:00 BST
Almac Group works to enable efficient manufacturing of remdesivir in response to Covid-19Almac Group works to enable efficient manufacturing of remdesivir in response to Covid-19
Almac Group works to enable efficient manufacturing of remdesivir in response to Covid-19

Remdesivir, an antiviral medication, is the first drug to be approved by the US Food and Drug Administration (FDA) as a treatment for COVID-19 after a trial showed it cut recovery time by five days.

In order to ultimately lower raw material usage, increase global yields and lower the overall cost of goods (COG) for the remdesivir development process, Almac Sciences has devised a plan to improve the overall route of synthesis to remdesivir including application of synthetic flow methodology and biocatalysis.

Hide Ad
Hide Ad

This investment supports efforts to combat the Covid-19 pandemic through the rapid process development and manufacturing of remdesivir.

“We are delighted to receive funding from the Therapeutics Accelerator to apply our skills in the fight against Covid-19,” said Dr Stefan Mix, Head of Biocatalysis, Almac Sciences.

“With the skillset of our multidisciplinary teams, we are confident that our developmental approach to the manufacture of remdesivir will positively impact patients’ lives who in urgent need, regardless of their location.”

Prof. Tom Moody, VP of Technology Development and commercialisation at Almac Sciences and Arran Chemical Company added: “This project highlights Almac’s strength in technology deployment through application of both innovative flow chemistry and biocatalysis technologies to support development of processes which are economical, greener and safer to perform.”

Hide Ad
Hide Ad

The Covid-19 Therapeutics Accelerator is an initiative launched by the Bill & Melinda Gates Foundation, Wellcome and Mastercard, with funding from an array of public and philanthropic donors to speed up the response to the COVID-19 pandemic by funding the identification, assessment, development and scale up of treatments.

This news comes just six months after Almac announced it was supporting two Covid-19 clinical studies in Sub-Saharan Africa through a grant also awarded from the Covid-19 Therapeutics Accelerator.

A message from the Editor:

Thank you for reading this story on our website. While I have your attention, I also have an important request to make of you.

In order for us to continue to provide high quality and trusted local news on this free-to-read site, I am asking you to also please purchase a copy of our newspaper whenever you are able to do so.

Hide Ad
Hide Ad

Our journalists are highly trained and our content is independently regulated by IPSO to some of the most rigorous standards in the world. But being your eyes and ears comes at a price. So we need your support more than ever to buy our newspapers during this crisis.

With the coronavirus lockdown having a major impact on many of our local valued advertisers - and consequently the advertising that we receive - we are more reliant than ever on you helping us to provide you with news and information by buying a copy of our newspaper when you can safely.

You can also enjoy unlimited access to the best news from across Northern Ireland and the UK by subscribing to newsletter.co.uk

With a digital subscription, you can read more than five articles, see fewer ads, enjoy faster load times, and get access to exclusive newsletters and content. Visit https://www.newsletter.co.uk/subscriptions now to sign up.

Thank you

Related topics:CraigavonCovid-19